Summary
Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures.
In this review, we discuss the cost effectiveness of stroke prevention for various risk factor—modification programmes and pharmacological interventions with aspirin (acetylsalicylic acid), ticlopidine and warfarin. Cost considerations and potential cost savings resulting from acute treatment are discussed for parenterally administered anticoagulants, such as heparin and nadroparin, and for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; r-tPA). Patients with multiple risk factors for stroke require more aggressive prevention strategies which are associated with a greater risk of complications. The rates of complications, particularly intracerebral haemorrhage, should be kept low to achieve cost benefits for warfarin and alteplase. Reduced hospital length of stay is the key factor in the implementation of cost-effective stroke therapies.
The analysis of future clinical trials of new stroke therapies should also include economic parameters, such as length of hospital stay and intensity of resource usage, to help guide formulary and therapeutic decisions.
Similar content being viewed by others
References
American Heart Association. 1992 Heart and stroke facts. Dallas: American Heart Association, 1992
Lanska DJ, Kryscio R. Geographic distribution of hospitalization rates, case fatality, and mortality from stroke in the United States. Neurology 1995; 45: 634–40
Emanuel EJ, Emanuel LL. The economics of dying — the illusion of cost savings at the end of life. N Engl J Med 1994; 330: 540–4
Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertension 1991; 9: 199–208
Rocella EJ, Lenfant C. Considerations regarding the cost and effectiveness of public and patient education programmes. J Hum Hypertens 1992; 6: 463–7
Gorelick PB. Stroke prevention: an opportunity for efficient utilization of health care resources during the coming decade. Stroke 1994; 25: 220–4
Broderick JP, Phillips SJ, Whisnant JP, et al. Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke 1989; 20: 577–82
Wolf PA, D’Agostino RB, O’Neal A, et al. Secular trends in stroke incidence and mortality: the Framingham study. Stroke 1992; 23: 1551–5
North American Symptomatic Carotid Endaretectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Engl J Med 1991; 325: 445–53
Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421–8
Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–38
Weinstein MC, Stason WB. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732–7
Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 408–13
Gafni A. On the costs of treating mild hypertension. J Gen Intern Med 1987; 2: 441–3
Millikan C, Futrell N. The strange story of aspirin and the prevention of stroke. J Stroke Cerebrovasc Dis 1995; 5: 248–54
Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238–48
Solomon DH, Hart RG. Antithrombotic therapies for stroke prevention. Curr Opin Neurol 1994; 7: 48–53
Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106
Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7
Oster G, Huse DM, Lacey MJ, et al. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 1994; 25: 1149–56
Van Gijn J, Algra A. Ticlopidine, trials, and torture. Stroke 1994; 25: 1097–8
Warlow CP. Ticlopidine, a new antithrombotic drug: but is it better than aspirin for long-term use? J Neurol Neurosurg Psychiatry 1990; 53: 185–7
Bladin CF, Norris JW. Relative benefits of ticlopidine and aspirin [letter]. Stroke 1994; 25: 2290
Roderick J, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993; 35: 219–26
Smurawska LT, Alexandrov AV, Bladin CF, et al. Cost of acute stroke care in Toronto, Canada. Stroke 1994; 25: 1628–31
Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469–73
Boston Area Anticoagulation Trial for Atrial Fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11
Stroke Prevention in Atrial Fibrillation investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527–39
Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839–45
European Atrial Fibrillation Trial Study group. Secondary stroke prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62
Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; II: 175–9
Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449–57
Gustafsson C, Asplund K, Britton M, et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457–60
Camarata PJ, Heros RC, Latchaw RE. Brain attack: the rationale for treating stroke as a medical emergency. Neurosurgery 1994; 34: 144–58
Rothrock JF, Hart RG. Antithrombotic therapy in cerebrovascular disease. Arch Intern Med 1991; 115: 885–95
Biller J, Love BB, Gordon DE. Antithrombotic therapy for ischemic cerebrovascular disease. Semin Neurol 1991; 11: 353–67
The International Stroke Trial Collaborative Group. The international stroke trial. Preliminary results part II: effects of heparin [abstract]. Stroke 1997; 28: 231
Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983; 14: 668–76
Duke RJ, Bloch RF, Turpie AG, et al. Intravenous heparin for prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986; 105: 825–8
Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588–93
Kay R, Woo J, Kreel L, et al. Stroke subtypes among Chinese living in Hong Kong: the Shatei stroke registry. Neurology 1992; 42: 985–7
Multicenter Acute Stroke Trial — Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145–50
Donnan G, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischaemic stroke [letter]. Lancet 1995; 345: 578–9
Multicentre Acute Stroke Trial — Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509–14
Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–25
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7
Levy DE, Brott TG, Haley Jr EC, et al. Factors related to hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25: 291–7
Fagan S, Morgenstern LB, Petitta A, et al. rt-PA Reduces length of stay and improves disposition following stroke [abstract]. Stroke 1997; 28: 272
Stegmayr B, Asplund K. Diabetes as a risk factor for stroke: a population perspective. Diabetologia 1995; 38: 1061–8
Working Group on Emergency Brain Resuscitation. Emergency Brain Resuscitation. Ann Intern Med 1995; 122: 622–7
Langehorn P, Williams BO, Gilchrist W, et al. Do stroke units save lives? Lancet 1993; 342: 395–8
Jorgensen HS, Nakayama H, Raaschou HO, et al. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of stay, and cost. A community-based study. Stroke 1995; 26: 1178–82
Baron JC, von Kummer R, del Zoppo GL. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1995; 26: 2219–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alexandrov, A.V., Smurawska, L.T., Bartle, W. et al. Cost Considerations in the Pharmacological Prevention and Treatment of Stroke. PharmacoEconomics 11, 408–418 (1997). https://doi.org/10.2165/00019053-199711050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199711050-00004